We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+9.98%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$142M
AUM Growth
-$2.52M
Cap. Flow
-$171K
Cap. Flow %
-0.12%
Top 10 Hldgs %
63.22%
Holding
44
New
12
Increased
5
Reduced
7
Closed
16

Top Buys

Rank Stock Value
1
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$6.37M
2
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$6.01M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$5.16M
4
OCRX
Ocera Therapeutics, Inc.
OCRX
+$4.93M
5
VCYT icon
Veracyte
VCYT
+$4.61M

Top Sells

Rank Stock Value
1
GERN icon
Geron
GERN
+$8.31M
2
GENT
GENTIUM SPA ADS
GENT
+$6.1M
3
DRTX
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
+$4.6M
4
ALBO
Albireo Pharma Inc
ALBO
+$4.2M
5
TRIB
Trinity Biotech
TRIB
+$4.11M

Sector Composition

Rank Sector Weight
1 Healthcare 44.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HPTX
1
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$16.4M 11.58%
811,113
-9,793
-1% -$231K
FLNA
2
Filana Therapeutics
FLNA
$48.8M
$13.6M 9.6%
399,670
-16,166
-4% -$429K
FURX
3
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$13.4M 9.48%
319,536
-29,820
-9% -$1.23M
NUWE icon
4
Nuwellis
NUWE
$160K
– –
0
– –
AMBI
5
DELISTED
Ambit Biosciences Corp
AMBI
$7.06M 4.99%
732,600
-150,859
-17% -$2.01M
OCRX
6
DELISTED
Ocera Therapeutics, Inc.
OCRX
$6.86M 4.84%
+527,797
New +$4.93M
INFI
7
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$6.23M 4.4%
+451,100
New +$6.37M
CCXI
8
DELISTED
ChemoCentryx, Inc.
CCXI
$5.79M 4.09%
+1,000,000
New +$5.16M
NSPH
9
DELISTED
NANOSPHERE INC. COM NEW
NSPH
$5.72M 4.04%
125,000
– –
AERI
10
DELISTED
Aerie Pharmaceuticals
AERI
$5.54M 3.91%
+308,429
New +$4.02M
AVEO
11
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$5.49M 3.88%
+300,000
New +$6.01M
VCYT icon
12
Veracyte
VCYT
$3.7B
$5.13M 3.62%
+353,925
New +$4.61M
SPHS
13
DELISTED
Sophiris Bio, Inc.
SPHS
$5.11M 3.61%
1,379,660
+99,660
+8% +$422K
CYNO
14
DELISTED
Cynosure, Inc. Class A
CYNO
$4.53M 3.2%
+170,000
New +$4.08M
ARCT icon
15
Arcturus Therapeutics
ARCT
$164M
$4.5M 3.18%
+35,714
New +$4.49M
HTWR
16
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$4.39M 3.1%
46,795
-13,205
-22% -$1.12M
VOLC
17
DELISTED
VOLCANO CORPORATION COM STK
VOLC
$4.37M 3.09%
200,000
+57,500
+40% +$1.27M
PLX icon
18
Protalix BioTherapeutics
PLX
$191M
$3.89M 2.75%
100,000
+60,099
+151% +$2.53M
HZNP
19
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.81M 2.69%
500,000
+400,000
+400% +$2.16M
CHTP
20
PUT
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
$3.22M 2.28%
+726,800
New +$2.46M
EYPT icon
21
EyePoint Inc
EYPT
$1.03B
$1.99M 1.4%
+50,000
New +$1.62M
AVNR
22
CALL
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$1.91M 1.35%
567,000
+367,000
+184% +$1.52M
LITS
23
Lite Strategy Inc
LITS
$32.8M
$1.26M 0.89%
7,883
– –
CBMX
24
DELISTED
CombiMatrix Corporation
CBMX
$849K 0.6%
+24,605
New +$974K
SVRA icon
25
Savara
SVRA
$1.12B
$599K 0.42%
18,499
-59,250
-76% -$1.9M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2013 Portfolio in Review

As of Q4 2013, Great Point Partners held 44 positions worth $142M, down 1.7% from $144M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Great Point Partners's Q4 2013 filing shows 12 new, 5 increased, 7 reduced and 16 closed positions. Its largest new stake was Infinity Pharmaceuticals, Inc.: 451,100 shares worth $6.23M. The largest sale was Geron, an estimated $8.31M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 42% a quarter earlier.

  • Great Point Partners's largest Q4 2013 buy was Infinity Pharmaceuticals, Inc.: 451,100 shares worth $6.23M.
  • Great Point Partners added most to Protalix BioTherapeutics in Q4 2013, an estimated $2.53M increase.
  • Great Point Partners's biggest Q4 2013 reduction was Streamline Health Solutions, cutting an estimated $2.87M.
  • Great Point Partners fully exited Geron in Q4 2013, selling an estimated $8.31M.
  • Great Point Partners's ten largest holdings make up 63% of its $142M portfolio in Q4 2013.
  • Great Point Partners opened 12 new positions and closed 16 in Q4 2013.
  • Great Point Partners's portfolio value fell 1.7% quarter-over-quarter to $142M.

Based on Great Point Partners's 13F filing for Q4 2013, filed 14 Feb 2014.